These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Schiffer CA Semin Hematol; 2008 Jan; 45(1):3-7. PubMed ID: 18179963 [TBL] [Abstract][Full Text] [Related]
5. Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. Steensma DP Leuk Res; 2006 Oct; 30(10):1227-33. PubMed ID: 16443272 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes. Bacher U; Haferlach C; Kröger N; Schnittger S; Kern W; Wiedemann B; Zander AR; Haferlach T Biol Blood Marrow Transplant; 2010 Jan; 16(1):1-11. PubMed ID: 20053328 [TBL] [Abstract][Full Text] [Related]
7. A comparative review of classification systems in myelodysplastic syndromes (MDS). Bennett JM Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011 [TBL] [Abstract][Full Text] [Related]
10. Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS). Fenaux P Semin Oncol; 2005 Aug; 32(4 Suppl 5):S11-5. PubMed ID: 16085012 [TBL] [Abstract][Full Text] [Related]
11. Treatment strategies in myelodysplastic syndromes. Atallah E; Garcia-Manero G Cancer Invest; 2008 Mar; 26(2):208-16. PubMed ID: 18259954 [TBL] [Abstract][Full Text] [Related]
12. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Dinmohamed AG; Visser O; van Norden Y; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M Eur J Cancer; 2014 Mar; 50(5):1004-12. PubMed ID: 24388662 [TBL] [Abstract][Full Text] [Related]
13. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. De Roos AJ; Deeg HJ; Davis S Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848 [TBL] [Abstract][Full Text] [Related]
14. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstöcker M; Rüter B; Sperr WR; Stauder R; Wells DA Leuk Res; 2007 Jun; 31(6):727-36. PubMed ID: 17257673 [TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Barzi A; Sekeres MA Cleve Clin J Med; 2010 Jan; 77(1):37-44. PubMed ID: 20048028 [TBL] [Abstract][Full Text] [Related]
16. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Mufti GJ Best Pract Res Clin Haematol; 2004 Dec; 17(4):543-57. PubMed ID: 15494293 [TBL] [Abstract][Full Text] [Related]
17. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Germing U; Aul C; Niemeyer CM; Haas R; Bennett JM Ann Hematol; 2008 Sep; 87(9):691-9. PubMed ID: 18575866 [TBL] [Abstract][Full Text] [Related]
19. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Jabbour E; Kantarjian HM; Koller C; Taher A Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499 [TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany. Gattermann N; Hofmann WK; Meessen A; Schmitz S; Tsamaloukas A; Vollmer T; Wedding U; Plesnila-Frank C; Schramm W; Berger K Onkologie; 2008 Sep; 31(8-9):477-84. PubMed ID: 18787357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]